Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD5789 (trifarotene) cream vs vehicle in moderate facial and truncal acne vulgaris
2015-002540-13Phase 3Completed
- Sponsor
- Galderma
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing CD5789 (trifarotene) cream arm with Vehicle cream arm (2 arms). Primary endpoint: Investigator Global Assessment (IGA) success rate at 12 weeks. Started Oct 2015; status: completed.
02
Drugs
trifarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2015-002540-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002540-13.